PRISM Stock IndexesCurrent Value% Change (Daily)% Change (Inception)Most ActiveTop % GainersTop % Losers
Cannabis$91.80-1.2%-8.2%TLRY 20,777CVSI 11.951%CGC -7.006%
EV$54.80-1.9%-45.2%NKLA 11,891SPAQ 5.556%FSR -6.675%
Gene Therapy$59.20-1.8%-40.8%BLUE 3,798BLCM 8.475%CLLS -23.006%
MedDevices$178.00-0.6%78.0%ATRS 5,230SSKN 16.87%BNKL -26.965%
MedDiagnostics$119.701.5%19.7%OPK 2,639GENE 82%CODX -6.349%
Solar$84.60-2.1%-15.4%HYSR 12,852SAENF 8.258%NOVA -7.061%
Uranium$113.20-5.3%13.2%UEC 8,154VEGYF 4.871%AZURF -21.739%
Vaccines & Cell Therapy$176.201.1%76.2%SRNE 11,433BCLI 28.571%NVAX -6.495%
Web 3.0$43.30-5%-56.7%MARA 26,770FTFT 5.076%NCTY -13.072%
Zombie$225.90-4.1%125.9%SNAP 31,585APRN 6.195%BILL -26.685%
NICOSIA (Reuters) -Cyprus voted on Sunday for a new president in an election that opinion polls indicate is unlikely to produce a clear winner, setting… [Read More]

Prism Daily

Music Festivals, Entertainment and the Metaverse

Brands, companies, and communities are increasingly turning to the metaverse as a way to connect. A study from December 2022 showed that 69% of users believe metaverse entertainment will transform social life. The famous 1960s rock festival Woodstock recently announced…

Artificial Intelligence and The Metaverse – AI Can Make a More Interactive Space

With both AI and Metaverse projects expanding at a rapid rate, it only makes sense that both technologies would complement each other. Artificial intelligence (AI) is seen as a critical factor in the growth of the metaverse and can enhance…

Meta Shares Soar 20% After-Hours on Q4 Revenue Beat

Meta (META) shares spiked 20% in extended trading after Meta and the Facebook parent company beat key revenue expectations and announced a $40 billion stock buyback plan. Some key numbers from the report are listed below: Q4 Revenue – $32.17 billion…

Feature Story

High Margins and Low Capital Costs A Winning Combination for Verde Bio

Scott Cox, CEO, Verde Bio
Scott Cox, CEO, Verde Bio

Mineral rights acquisitions companies benefit directly from increasing commodity prices

Oil and gas stocks have long been popular with income-focused investors. When commodity prices are high, investors benefit from dividends from the resulting rising share prices. Mineral rights investments offer all the advantages of a typical oil and gas portfolio, with the rewards brought about by increasing energy prices, without taking on the burden of drilling and operating costs.

Verde Bio Holdings (OTCQB: VBHI) is a mineral rights and acquisitions specialist acquiring interests in lower risk, onshore oil and gas properties within the major oil and gas plays in the United States. The company is revenue-producing, with a portfolio of over 400 wells across seven states, and 24 operators in eight reservoirs.

We spoke to Verde Bio CEO, Scott Cox, to find out more.

(more…)

Traders Lens

I can not recall seeing the 20D, 50D and 200D moving averages all consolidating as they are right now.

I can not recall seeing the 20D, 50D and 200D moving averages all consolidating as they are right now. In the midst of very significant events – i.e. earnings, more Fed action/inaction, employment numbers coming etc, we have serious price congestion either side of 400 on the $SPY. No one can say for certain what this means, but I would bet on significant upcoming volatility and once direction is confirmed – maybe above 410 or below 390 – we should see a new primary trend established. This will be fascinating.

[More Traders Lens]

Prism View

Mesoblast Limited Resubmits Biologics License Application to FDA; New Data Shows Long-Term Survival Outcomes

Mesoblast Limited, (Nasdaq: MESO; ASX:), a global leader in allogeneic cellular medicines for inflammatory diseases has resubmitted its Biologics License Application (BLA) for approval of remestemcel-L in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD). Remestemcel-L…

Lexaria Bioscience: Charting a Path to Commercial Success

Lexaria Bioscience (Nasdaq: LEXX), is charting a path to commercial success with its proprietary drug delivery technology, DehydraTECH™. The company closed out a year of milestone achievements with positive results from its human hypertension study, positioning Lexaria strongly as it pursues…

Quince Therapeutics Sells Legacy Portfolio to Lighthouse Pharmaceuticals

Biopharmaceutical company, Quince Therapeutics (Nasdaq: QNCX), has sold its legacy small molecule protease inhibitor portfolio to Lighthouse Pharmaceuticals. As a result of the sale, Quince expects to benefit from the reduction of more than $500,000 of annualized expenses associated with…

Lipella Reports Successful Top Line Results in Phase 2a Study

Clinical-stage biotechnology company, Lipella Pharmaceuticals (LIPO) has released positive top line results from its Phase 2a…

Former GW Pharmaceuticals President Joins Lexaria

 Lexaria Bioscience (Nasdaq:LEXX) has appointed the former President of GW Pharmaceuticals USA, Julian Gangolli, as a…

Spruce Biosciences Enters Strategic Partnership to Deliver Tildacerfont to Japanese Market

Late-stage biopharmaceutical company, Spruce Biosciences (Nasdaq: SPRB), has announced an exclusive licensing agreement with Kaken Pharmaceuticals…

As Investors Continue to Gain Interest in the Emerging Name Image and Likeness (NIL) Industry, OpenLocker Steps onto the Court as an Early-Mover in Digital Sports Collectables

The Player: OpenLocker Holdings, Inc. (OTCQB:OLKR)  OpenLocker Holdings is a technology platform for athletes and brands…